Results - Announcements
Symbiotec Pharmalab Ltd share price gained 2.90% to Rs 1270.9 after the company's net profit surged by 267.85% to Rs 51.72 crore, while revenue from operations increased sharply by 28.32% to Rs 279.93 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, easing 5.17%. It has improved by 2.18% over last one week and crept higher by 2.72% in last one month while the market capitalization of Symbiotec Pharmalab Ltd has remained flat
Profit before tax (PBT) of Symbiotec Pharmalab Ltd stood at Rs 64.04 crore in Q3 FY26, jumping 42.88% year-on-year, and expanding by 265.32% quarter-on-quarter. EBITDA came in at Rs 91 crore, surging by 65.19% YoY and rallying 103.79% sequentially.
Total expenses grew marginally by 7.96% to Rs 210.29 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 79.62 crore, posting a minor increase of 5.37% YoY, while employee benefits expense was at Rs 46.96 crore, inching up 1.16% YoY.
For the TTM ended FY26, revenue from operations improved 15.65% to Rs 869.15 crore, while net profit registered a growth of 13.54% to Rs 109.9 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 20659% to Rs 234.74 crore, and PBT saw a minor gain of 4.34% to Rs 153.36 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 174.59 crore in FY26, as against Rs 47.26 crore in FY25.